This contract opportunity involves the establishment of non-exclusive discount agreements for the drug Trastuzumab, classified under ATC code L01FD01, in the regions of Lower Saxony, Bremen, and Saxony-Anhalt. The focus is on parenteral preparations made from finished medicinal products for oncology
311 days left to bid. Opened 1 years ago, deadline 21 Apr 2027.
This contract opportunity involves establishing a non-exclusive discount agreement for medications containing the active ingredient Teriparatide (ATC Code: H05AA02). The contract will be effective from December 1, 2025, to November 30, 2027, with the option for suppliers to enter into the contract a
This contract opportunity involves establishing a non-exclusive discount agreement for the medication Omalizumab (ATC Code: R03DX05) in Germany. The contract will be effective from December 1, 2024, to November 30, 2026, with the option for suppliers to enter into the contract at any time during thi
UKHSA is conducting market research to understand oligonucleotide manufacturing capabilities in the UK with the goal of strengthening domestic production for biosecurity and pandemic preparedness.
UKHSA seeks market information on oligonucleotide manufacturing capabilities in the UK and globally to strengthen domestic biosecurity and inform future sourcing decisions.
Short-term managed equipment service contract for catheterisation laboratories at Chelsea and Westminster Hospital supporting a multi-site NHS tender process across North West London.
Imperial College Healthcare NHS Trust requires a managed equipment service provider for catheterisation laboratories across North West London's acute provider network.
